Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Short Interest Update

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) was the recipient of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 742,800 shares, an increase of 86.3% from the February 13th total of 398,700 shares. Based on an average daily volume of 817,700 shares, the short-interest ratio is presently 0.9 days. Approximately 1.5% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a "buy" rating and issued a $25.00 price target on shares of Milestone Pharmaceuticals in a report on Monday.

Milestone Pharmaceuticals Price Performance

NASDAQ:MIST traded down $0.03 during trading hours on Tuesday, hitting $2.38. The stock had a trading volume of 2,797,714 shares, compared to its average volume of 412,472. The company has a 50 day simple moving average of $2.02 and a two-hundred day simple moving average of $1.81. The company has a debt-to-equity ratio of 2.18, a current ratio of 15.40 and a quick ratio of 15.40. Milestone Pharmaceuticals has a one year low of $1.12 and a one year high of $2.75. The firm has a market capitalization of $126.92 million, a price-to-earnings ratio of -2.94 and a beta of 1.83.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Jones Financial Companies Lllp lifted its holdings in shares of Milestone Pharmaceuticals by 1,000.0% during the 4th quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company's stock worth $26,000 after acquiring an additional 10,000 shares during the last quarter. National Bank of Canada FI lifted its holdings in shares of Milestone Pharmaceuticals by 163.4% during the 4th quarter. National Bank of Canada FI now owns 18,700 shares of the company's stock worth $44,000 after acquiring an additional 11,600 shares during the last quarter. PVG Asset Management Corp bought a new stake in shares of Milestone Pharmaceuticals during the 3rd quarter worth $46,000. Atria Investments Inc lifted its holdings in shares of Milestone Pharmaceuticals by 44.4% during the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company's stock worth $61,000 after acquiring an additional 12,430 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Milestone Pharmaceuticals during the 4th quarter worth $73,000. 86.18% of the stock is owned by institutional investors.

Remove Ads

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.